T. Rowe Price Associates
BMRN icon

T. Rowe Price Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$7.58M Buy
137,926
+5,577
+4% +$307K ﹤0.01% 1174
2025
Q1
$9.36M Sell
132,349
-460,044
-78% -$32.5M ﹤0.01% 1125
2024
Q4
$38.9M Sell
592,393
-71,162
-11% -$4.68M ﹤0.01% 821
2024
Q3
$46.6M Sell
663,555
-319,785
-33% -$22.5M 0.01% 773
2024
Q2
$81M Sell
983,340
-118,973
-11% -$9.8M 0.01% 590
2024
Q1
$96.3M Sell
1,102,313
-503,670
-31% -$44M 0.01% 559
2023
Q4
$155M Buy
1,605,983
+401,152
+33% +$38.7M 0.02% 459
2023
Q3
$107M Sell
1,204,831
-86,847
-7% -$7.68M 0.02% 502
2023
Q2
$112M Sell
1,291,678
-2,369
-0.2% -$205K 0.02% 501
2023
Q1
$126M Buy
1,294,047
+366,211
+39% +$35.6M 0.02% 471
2022
Q4
$96M Buy
927,836
+316,129
+52% +$32.7M 0.02% 503
2022
Q3
$51.9M Buy
611,707
+86,888
+17% +$7.37M 0.01% 637
2022
Q2
$43.5M Sell
524,819
-1,064,526
-67% -$88.2M 0.01% 920
2022
Q1
$123M Buy
1,589,345
+370,312
+30% +$28.6M 0.01% 665
2021
Q4
$108M Buy
1,219,033
+4,146
+0.3% +$366K 0.01% 740
2021
Q3
$93.9M Sell
1,214,887
-445,429
-27% -$34.4M 0.01% 790
2021
Q2
$139M Sell
1,660,316
-250,194
-13% -$20.9M 0.01% 672
2021
Q1
$144M Sell
1,910,510
-154,072
-7% -$11.6M 0.01% 656
2020
Q4
$181M Buy
2,064,582
+109,300
+6% +$9.58M 0.02% 552
2020
Q3
$149M Buy
1,955,282
+515,857
+36% +$39.2M 0.02% 551
2020
Q2
$178M Buy
1,439,425
+25,517
+2% +$3.15M 0.02% 497
2020
Q1
$119M Sell
1,413,908
-702,146
-33% -$59.3M 0.02% 525
2019
Q4
$179M Sell
2,116,054
-128,267
-6% -$10.8M 0.02% 504
2019
Q3
$151M Sell
2,244,321
-51,883
-2% -$3.5M 0.02% 507
2019
Q2
$197M Sell
2,296,204
-185,337
-7% -$15.9M 0.03% 470
2019
Q1
$220M Buy
2,481,541
+207,251
+9% +$18.4M 0.03% 441
2018
Q4
$194M Sell
2,274,290
-158,692
-7% -$13.5M 0.03% 443
2018
Q3
$236M Sell
2,432,982
-88,501
-4% -$8.58M 0.03% 444
2018
Q2
$238M Buy
2,521,483
+247,675
+11% +$23.3M 0.04% 430
2018
Q1
$184M Sell
2,273,808
-148,606
-6% -$12M 0.03% 481
2017
Q4
$216M Buy
2,422,414
+413,363
+21% +$36.9M 0.04% 444
2017
Q3
$187M Buy
2,009,051
+368,486
+22% +$34.3M 0.03% 465
2017
Q2
$149M Buy
1,640,565
+153,834
+10% +$14M 0.03% 505
2017
Q1
$131M Buy
1,486,731
+295,308
+25% +$25.9M 0.02% 524
2016
Q4
$98.7M Sell
1,191,423
-1,395,706
-54% -$116M 0.02% 600
2016
Q3
$239M Sell
2,587,129
-938,185
-27% -$86.8M 0.05% 377
2016
Q2
$274M Sell
3,525,314
-2,693,446
-43% -$210M 0.06% 327
2016
Q1
$513M Sell
6,218,760
-1,808,053
-23% -$149M 0.11% 213
2015
Q4
$841M Buy
8,026,813
+491,119
+7% +$51.4M 0.18% 137
2015
Q3
$794M Sell
7,535,694
-461,769
-6% -$48.6M 0.18% 135
2015
Q2
$1.09B Sell
7,997,463
-177,126
-2% -$24.2M 0.23% 112
2015
Q1
$1.02B Buy
8,174,589
+6,235,807
+322% +$777M 0.21% 117
2014
Q4
$175M Sell
1,938,782
-98,611
-5% -$8.91M 0.04% 466
2014
Q3
$147M Sell
2,037,393
-116,132
-5% -$8.38M 0.03% 500
2014
Q2
$134M Sell
2,153,525
-146,424
-6% -$9.11M 0.03% 550
2014
Q1
$157M Sell
2,299,949
-376,976
-14% -$25.7M 0.04% 496
2013
Q4
$188M Sell
2,676,925
-167,305
-6% -$11.8M 0.04% 445
2013
Q3
$205M Sell
2,844,230
-97,060
-3% -$7.01M 0.05% 395
2013
Q2
$164M Buy
+2,941,290
New +$164M 0.04% 439